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While cardiovascular clinical and basic scientists have been 
improving the methods of preventing and treating a wide 
variety of cardiovascular diseases, biostatisticians have sim- 
ilarly been making important advances in the reporting and 
understanding of medical and surgical data, and particularly 
of data after cardiac valve surgery. The report in this issue of 
the Journal by Lindblom and coworkers (1) from the Karo- 
linska Hospital in Stockholm gives a very nice example of 
the degree to which sophisticated “number crunching” of 
biomedical data can provide some important conclusions 
and insights on well established therapies and also provide 
insights to further enhance these therapies. 
New guidelines for actuarial analysis. Improvement in 
reporting valve surgery data is an outgrowth of recent 
conferences on valve surgery at which the same morbid 
events were described by a wide variety of terms, a confus- 
ing vocabulary and varying statistical methods. Noting this, 
the two major American cardiothoracic surgical societies, 
The Society of Thoracic Surgeons and The American Asso- 
ciation for Thoracic Surgery, formed an ad hoc committee to 
standardize terminology representing the most broadly 
based, widely accepted definitions of valve-related morbid- 
ity and mortality and also to provide statistical guidelines for 
the reporting of these data in a rational and standardized 
fashion (2). 
The Mayo Clinic and the University of Oregon were the 
first groups to use actuarial analysis of morbid events 
following valve replacement with the Starr-Edwards valve. 
These data analyses were based on the earlier actuarial data 
concepts of Cutler and Ederer (3). Actuarial survival curves 
have been applied increasingly to a multitude of valve 
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studies, often in a meaningless and sometimes misleading 
fashion, by using inadequate numbers, imprecise data 
points, and sometimes omitting standard errors and confi- 
dence limits. 
The present study. The data of Lindblom et al. (1) are 
remarkably good and serve as a model of data aquisition and 
statistical reporting by providing us with a very large, 
consecutive series from a homogeneous population in which 
the patients with the same valve device, the Bjork-Shiley 
valve, were completely followed up over a long period. After 
many studies that have reported on large heterogeneous 
populations undergoing valve surgery, there appears to be an 
increasing need for this kind of “pure” study that helps to 
distinguish patient-related from device-related morbidity. 
Their study was particularly noteworthy for its 100% follow- 
up with a very high degree of autopsy-documented deaths. A 
rate of >5% lost to follow-up is considered invalid in some 
statistical circles because in the group of lost patients there 
may have been morbid events that would have significantly 
altered the study results. The authors’ classification of 
mortality is exact, although I believe that sudden unex- 
plained death should always be considered a cardiac death, 
most probably with an arrhythmic basis. The data on patient 
age are also compatible with those from many valve replace- 
ment populations from Europe in contrast to the older 
American valve replacement population. This fact may 
appear to alter morbidity statistics from series to series. In 
fact, recent data suggest that certain valves, such as porcine 
valves, may appear to perform better in series with elderly 
patients than in series with younger patients, because elderly 
patients may die of other causes before the valve deterio- 
rates or produces morbid events (4). 
The authors (1) use as their control the “expected” 
surviva/ of the Swedish population. These are calculations 
based on the entire Swedish population, which contains 
many other forms of disease and is similar in theory (but less 
so in scope) to the often used United States Public Health 
statistical data on age- and gender-matched individuals in 
this country. This control group has been criticized as 
inappropriate for many studies dealing with medical and 
surgical treatment of coronary artery disease because it 
suggests that the survival rate of the general population is 
affected by the disease, particularly ischemic heart disease, 
under study. To the authors’ credit, they withdrew the 
patients in this series who died after valve replacement from 
the survival data in the general population. They then 
compared the observed survival rate with the expected 
survival rate to determine whether patients were “cured” by 
inserting a valve device. They determined that there were no 
“cures,” that the survival rates of the patients did not, in 
most instances, return to the normal expected survival rates 
01990 by the American College of Cardiology 0735-1097190/$3.50 
JACC Vol. 15, No. 3 
March I. 1990:574-j 
COHN 515 
EDITORIAL COMMENT 
before their age- and gender-matched cohorts in the general probably prevents, at least from early data, onset of chronic 
population. This can be explained by two factors: 1) the congestive failure so common in patients after mitral valve 
number of deaths from cardiac disease related to the pa- surgery. Although the authors did not detail left ventricular 
tient’s morbid factors, such as chronic congestive failure at function or clinical functional status in their analysis, it is 
the time of surgery, and 2) the prosthetic valve-related presumed that the relatively high late cardiac death rate was 
morbid factors such as anticoagulant-related hemorrhage a result of chronic left ventricular dysfunction as well as the 
and thromboembolism. complications of the valve device itself. 
The authors (I) conclude that there are three approaches 
to improve “curability” of patients after valve surgery. 
First, improve the operative circumstances; they note that in 
recent times, particularly in the patient with ventricular 
hypertrophy undergoing aortic valve replacement, car- 
dioplegia improved their results. Second, improve the valve 
design. This has been done with the new bileaflet central 
flow disc valve with which morbidity rates appear to be 
better than those with the Bjork-Shiley valve, no longer on 
the United States market. And finally, they believe that 
perhaps these data should serve as a stimulus for earlier 
referral of patients, particularly those with volume-loaded, 
regurgitant lesions of the aortic and mitral valves. This last 
point is obviously controversial because the authors admit 
that one may be substituting “prosthetic” valve disease for 
native valve disease. I suggest that, particularly for mitral 
regurgitation, we look very critically at earlier referral, 
where the possibility of valve repair is high and where 
papillary muscle annular continuity retains the normal shape 
of the left ventricle, which enhances cardiac output and 
The effect of earlier referral of patients, better operations 
and better prostheses should be evaluated by the types of 
statistical methods presented in this study. Using the in- 
creasingly accepted guidelines for reporting results of valve 
surgery, it is anticipated that increasing numbers of centers, 
as well as the group from Karolinska Hospital, will have the 
wherewithal to present their data. 
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